Bayer cancels asundexian phase III study program
Germany’s Bayer AG said on Sunday it is cancelling a phase III study program to investigate the efficacy and safety of asundexian, an oral Factor XIa (FXIa) inhibitor.
Germany’s Bayer AG said on Sunday it is cancelling a phase III study program to investigate the efficacy and safety of asundexian, an oral Factor XIa (FXIa) inhibitor.
Il Santo del giorno: il santo di oggi e il calendario delle celebrazioni di tutti santi e ricorrenze dell’anno
🙏Srimad Bhagavad Gita Chapter 14 Verse 11🙏Do not be proud when Sattva Guna increases.🙏Hare Krishna🙏
AstraZeneca said on Tuesday it had initiated the worldwide withdrawal of its COVID-19 vaccine due to a “surplus of available updated vaccines” since the pandemic.
An official journal of the European Society of Cardiology. Publishes high quality material, both clinical and scientific, on all aspects of Cardiovascular Medicine – including…
AstraZeneca is removing its Covid vaccine worldwide, months after the pharmaceutical giant admitted that it can cause a rare and dangerous side effect.
McKesson Corp reported weaker-than-expected quarterly revenue and profit on Tuesday due to slump in demand for the company’s branded and specialty drugs that dragged sales…
Electrical artifact is seen in 100% of patients on telemetry, and it can mimic a wide range of arrhythmias. This video reviews various ways to…
Diagnostics firm Bio Rad Laboratories reiterated its 2024 sales growth forecast on Tuesday, weighed by persistently weak spending by biotech companies and sluggish demand in…
The BUDAPEST CRT Upgrade trial marked the pioneering attempt to evaluate the efficacy and safety of a cardiac resynchronization therapy (CRT) upgrade in comp…
The shape of Doppler velocity tracings in obstructive hypertrophic cardiomyopathy offers insights into its pathophysiology. Inflection points are the points on a curve where its…